Together, these results suggest that inhibition of leukemia development by PF-06747143 in vivo possibly utilizes a combination of different mechanisms of action related to interruption of CXCR4 signaling, leukemic cell mobilization from the growth factor rich BM, and rapid destruction of leukemic cells triggered by the cytotoxic effector function. Here, CXCR4 is linked to leukemia.